Gibco HT Supplement is a liquid mixture of sodium hypoxanthine (10 mM) and thymidine (1.6 mM). HT-supplemented medium is suitable for post-selection rescue to overcome the effects of residual intracellular aminopterin. Once the de novo biosynthesis pathway for nucleosides has been reestablished, HT supplementation can be discontinued.
cGMP Manufacturing and Quality System For supply chain continuity, we manufacture Gibco HT Supplement (100X) at two separate facilities located in Grand Island, NY and Scotland, UK. Both sites are compliant with cGMP manufacturing requirements and are certified to ISO 13485 and are certified to the ISO 13485 standard.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Concentration100 X
Quantity50 mL
Shelf Life18 Months
Shipping ConditionRoom Temperature
FormLiquid
Product TypeHT Supplement
SterilitySterile-filtered
Unit SizeEach
Contents & Storage
Storage conditions: 2°C to 8°C Shipping conditions: Room temperature Shelf life: 18 months from date of manufacture
Have questions about this product? Ask our AI assisted search.
This is an AI-powered search and may not always get things right. You can help us make it better with a thumbs up or down on individual answers or by selecting the “Give feedback" button. Your search history and customer login information may be retained by Thermo Fisher and processed in accordance with our
Privacy Notice.
Documents & Downloads
Certificates
Search by lot number or partial lot number
Search
Lot #Certificate TypeDateCatalog Number(s)
3233971Certificate of AnalysisJun 13, 202511067030
2451878Certificate of AnalysisJan 29, 202511067030
2451880Certificate of AnalysisJan 29, 202511067030
2451884Certificate of AnalysisJan 29, 202511067030
2451898Certificate of AnalysisJan 29, 202511067030
5 results displayed, search above for a specific certificate
Search citations by name, author, journal title or abstract text
Search
Citations & References
Abstract
Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty.
Authors:Tagalakis AD, Graham IR, Riddell DR, Dickson JG, Owen JS,
Journal:J Biol Chem
PubMed ID:11278248
'Apolipoprotein (apo) E is a polymorphic plasma protein, synthesized mainly by liver. Here, we evaluate whether synthetic DNA-RNA oligonucleotides (chimeraplasts) can convert a dysfunctional isoform, apoE2 (C --> T, R158C), which causes Type III hyperlipidemia and premature atherosclerosis, into apoE3. First, we treated recombinant Chinese hamster ovary cells stably secreting ... More